Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Researchers have unveiled a new DNA-based therapy that silences the PCSK9 gene to lower cholesterol without statin side effects. Early results show dramatic reductions in cholesterol levels, offering ...

Discover how cholesterol-lowering drug targets may reduce dementia risk through genetic insights. Keep reading.

Gut microbiota produce trimethylamine, which enters the liver via the portal circulation and is primarily oxidized by FMO3 to produce TMAO. TMAO upregulates hepatic PCSK9 gene expression while ...

An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional ...

Scientists have developed a breakthrough therapy that could revolutionise the treatment of high cholesterol, which currently ...

Cholesterol synthesis and gallstone formation are promoted by trimethylamine-N-oxide (TMAO), a derivative of trimethylamine, which is a metabolite of gut microbiota. However, the underlying mechanisms ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...

Gut microbiota produce trimethylamine, which enters the liver via the portal circulation and is primarily oxidized by FMO3 to produce TMAO. TMAO upregulates hepatic PCSK9 gene expression while ...

A revolutionary gene-silencing technique has shown that a single treatment can dramatically lower LDL cholesterol levels for over a year—without permanently altering DNA. Could this be the future of ...